This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Good morning everyone. Thank you for joining us. I am Steve Beuchaw from the Morgan Stanley Medtech team. It is my pleasure to have you all here and to introduce Align Technology. We have Ken Arola, CFO of the company.
Before we begin though, please do note that all important disclosures including all personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. It’s a riveting read. So Ken, I would like to open the floor to you for any opening remarks.
Sure. I just like to thank everybody for being this morning at Morgan Stanley Conference, just a little bit of Align Technology for those of you who don’t know. We have been in business for about 12 to 13 years as a public company. We’ve helped about 2 million patients get treatment and generated over about $2 billion in revenue over that time period along the way was delivering about 75 to 80 million individual class II medical devices which we call aligners.
Our strategy for the company really focuses around four key areas. One of them being clinical innovation giving doctors what they want to treat the patient effectively and get the results that they are looking for and I am sure we’ll get some questions on that at this morning. The other one is the driving consumer demand and educating patients so they can walk into doctor’s offices understanding the capabilities of what Align – Invisalign can do for them and should basically challenge a doctor if that something they want as a formal treatment.